Gastric cancer prewarning and early diagnosis system
The book explores recent developments in the application of nanotechnology in the early detection of gastric cancer. It discusses various aspects, such as screening for gastric cancer-associated biomarkers; establishing new ultrasensitive detection methods based on nanoparticle labeling and nanoeffe...
Saved in:
| Other Authors | |
|---|---|
| Format | Electronic eBook |
| Language | English |
| Published |
[Place of publication not identified] :
Springer,
2017.
|
| Edition | 1st ed. 2017. |
| Series | Translational medicine research,
|
| Subjects | |
| Online Access | Full text |
| ISBN | 9789402409512 9789402409499 |
| ISSN | 2451-991X |
| Physical Description | 1 online resource |
Cover
Table of Contents:
- Preface; Contents; Chapter 1: Background of Gastric Cancer Prewarning and Early Diagnosis System; 1.1 Current Clinical Status of Gastric Cancer; 1.2 Main Diagnostic Methods for Gastric Cancer in the Clinical Setting; 1.2.1 Endoscopy; 1.2.2 Imaging Diagnosis; 1.2.3 Histopathological Examination; 1.2.4 Serological Biomarker Examination; 1.3 Concept of Gastric Cancer Prewarning and Early Diagnosis System; References; Chapter 2: Human Serum Protein Markers for Gastric Cancer Detection; 2.1 Introduction; 2.2 Broad-Spectrum Tumor Serum Markers in the Detection of Gastric Cancer; 2.2.1 CEA.
- 2.2.2 CA19-92.2.3 CA125; 2.2.4 AFP; 2.2.5 M2-Pyruvate Kinase; 2.3 Gastric Secreted Protein as Serum Markers of Gastric Cancer; 2.3.1 PGI; 2.3.2 PGII; 2.3.3 Gastrin 17; 2.3.4 TFF3; 2.4 Gastric Infection and Gastric Cancer-Associated Antibodies; 2.4.1 H. pylori Antibody; 2.4.2 CagA Antibody; 2.4.3 p53 Antibody; 2.4.4 Anti-parietal Cell Antibody; 2.5 Inflammation Signaling Molecules in the Diagnosis of Gastric Cancer; 2.5.1 SAA (Serum Amyloid A); 2.5.2 MIF (Macrophage Migration Inhibitory Factor); 2.5.3 Leptin; 2.5.4 Dickkopf; 2.5.5 Olfactomedin 4; 2.5.6 VAP-1 (Vascular Adhesion Protein-1).
- 2.6 Protease and Protease Inhibitors in the Diagnosis of Gastric Cancer2.6.1 UPA; 2.6.2 Cathepsin B; 2.6.3 HMW Kininogen; 2.7 Apoptosis-Related Molecules; 2.7.1 Cytokeratin 18; 2.8 Cell Division-Related Molecules; 2.8.1 RegIV; 2.8.2 S100A6; 2.8.3 IPO-38; 2.9 Plasma Coagulation Factors; 2.9.1 Thrombin Light Chain A; 2.9.2 Fibrinopeptide A; 2.10 Conclusions; References; Chapter 3: Screening and Detection of Gastric Cancer Circulating MicroRNA Biomarkers; 3.1 MicroRNA and Gastric Cancer; 3.1.1 MicroRNA; 3.1.2 MicroRNA and Gastric Cancer; 3.2 Circulating MicroRNA Biomarkers for Gastric Cancer.
- 3.2.1 Background3.2.2 Advantages on Circulating MicroRNA Biomarkers; 3.2.3 Correlation Between Tissue miRNAs and Circulating miRNAs; 3.2.4 Challenges on Screening of Circulating MicroRNA Biomarkers; 3.2.5 Circulating MicroRNA Biomarkers for Gastric Cancer; 3.2.6 Conclusions and Prospects; 3.3 Nanoparticle-Based Optical Detection of MicroRNA; 3.3.1 Background; 3.3.2 Characteristics of MicroRNA Detection; 3.3.3 Fluorescence-Based MicroRNA Detection; 3.3.3.1 Quantum Dots; 3.3.3.2 Silver Nanoclusters; 3.3.3.3 Magnetic Nanoparticles and Others; 3.3.4 Scattering-Based MicroRNA Detection.
- 3.3.4.1 SERS3.3.4.2 Other Scattering; 3.3.5 Colorimetry-Based MicroRNA Detection; 3.3.6 Conclusions and Outlook; References; Chapter 4: Screening and Identification of Biomarkers from Gastric Cancer Saliva Metabolites; 4.1 Introduction; 4.2 Molecular Identification in Saliva of Gastric Cancer Patients; 4.3 Biomarkers in Saliva of Gastric Cancer Patients and Metabolic Characteristics; 4.4 Diagnosis of Gastric Cancer Using the Identified Biomarkers; 4.5 Saliva Markers for Gastric Cancer Detection; References.